KalVista Pharmaceuticals presented data on the hereditary angioedema (HAE) attack journey and a patient preference study at the 2023 US Hereditary Angioedema Association (HAEA) National Summit in Orlando, Florida, from 20-23 July 2023.
The following presentations occurred at the HAEA Summit:
- In Their Own Words – Patient Descriptions of the Earliest Recognition of HAE Attack Onset. Presenter: Dr. Michael E. Manning
- Recognizing the Importance of Early On-Demand Treatment in the HAE Attack Journey. Presenter: Dr. Michael E. Manning
- Preferences of People with Hereditary Angioedema for On-Demand Treatment: A US-Based Qualitative Study. Presenter: Dr. Paula J. Busse
Andrew Crockett, Chief Executive Officer of KalVista, commented: “The data presented at HAEA adds to the growing evidence that there remains an important unmet need for both people using only on-demand therapies as well as those on long-term prophylaxis.”
By offering the first oral, on-demand medication in sebetralstat, we intend to address this gap in treatment as well as enable future physician/patient discussions about new options that may allow people with HAE to live better lives.”
(Source: KalVista Pharmaceuticals)
